Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | RAD52 | P43351 | 2/20 | 0.39 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962180 | 1.00 | RXFP1 (0.43) | RXFP1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL5962179 | 0.89 | LMNA (0.38) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| SCHEMBL5962181 | 0.89 | LMNA (0.38) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| SCHEMBL3704534 | 0.88 | KDM4E (0.39) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| SCHEMBL5962119 | 0.85 | RXFP1 (0.46) | RXFP1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL3696499 | 0.83 | LMNA (0.46) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| SCHEMBL5962241 | 0.83 | ALDH1A1 (0.52) | RXFP1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL5962235 | 0.82 | LMNA (0.48) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| SCHEMBL3701955 | 0.82 | LMNA (0.46) | ALDH1A1KDM4EHSD17B10HPGDKMT2A | |
| SCHEMBL6033107 | 0.81 | TP53 (0.38) | ALDH1A1KDM4EHSD17B10HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569484-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8569484-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| WO-2010136817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | RXFP1 4237/4885ALDH1A1 847/4885KDM4E 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.